A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
This study tests a new medication called TNG456, either by itself or combined with another drug called abemaciclib, for people with advanced solid tumors. Researchers want to see if these treatments are safe and how well they work against cancers that are missing a specific gene called MTAP.
You may be able to join if you are 18 or older, can swallow pills, and have a solid tumor missing the MTAP gene where standard treatments haven't worked or aren't an option. Certain prior treatments, pregnancy, or severe infections will mean you cannot participate.
Participants will take the study treatments by mouth, as the study is testing different doses to find the safest and most effective amount. Your health and your tumor's response will be closely monitored by the medical team throughout the study.
The study is currently recruiting participants at locations in Arizona and California, United States. Up to 191 people will take part in this trial.
- 1Tests a new pill called TNG456 for cancers with a missing MTAP gene
- 2May involve taking TNG456 alone or alongside another cancer drug
- 3Currently recruiting patients at select centers in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.